Our strategy allows the generation of “universal” effector T cells for a donor-unrestricted application of ACT to any patient bearing CD1c-expressing leukemia: moreover, in an allogeneic HSCT setting, the risk of GvHD should be minimized upon ACT given the absence of CD1c on parenchymatous tissues. The gene discussed is CD1C; the disease is leukemia.